Genmab and AbbVie’s Epcoritamab Combination Therapy Shows 51% PFS Improvement in DLBCL Trial

  • Genmab and AbbVie’s Phase 3 EPCORE DLBCL-2 trial showed a 51% reduction in the risk of disease progression or death in newly diagnosed DLBCL patients with an IPI score of 2 to 5.
  • The trial compared epcoritamab plus R-CHOP versus R-CHOP alone, demonstrating a statistically significant improvement in progression-free survival (PFS).
  • Epcoritamab, a T-cell engaging bispecific antibody, was well-tolerated when combined with standard-of-care R-CHOP.
  • The trial enrolled patients with various subtypes of large B-cell lymphoma, including DLBCL, NOS, HGBL, FL3B, TCHR LBLC, and EBV+ DLBCL.
  • Genmab and AbbVie plan to engage global regulatory authorities for potential approval.

The positive Phase 3 results for epcoritamab in combination with R-CHOP mark a significant milestone in the treatment of diffuse large B-cell lymphoma, potentially reshaping the frontline therapy landscape. This collaboration between Genmab and AbbVie underscores the growing importance of bispecific antibodies in oncology, particularly for aggressive blood cancers. The success of this trial could pave the way for broader adoption of bispecific antibody therapies in other hematologic malignancies.

Regulatory Pathway
The pace at which Genmab and AbbVie secure regulatory approvals for epcoritamab plus R-CHOP will determine its market entry timing and competitive positioning.
Commercial Strategy
How Genmab and AbbVie plan to commercialize the combination therapy globally, given their shared and separate responsibilities in different regions.
Pipeline Expansion
Whether the success of this trial will accelerate the development of other bispecific antibody combinations in Genmab and AbbVie’s pipelines.